Can the Longevity Compound Rapamycin Rescue Brain Tissue in Age-Related Diseases in Old Mice?
ISEF · 2019 Translational Medical Science
Overview
Rapamycin is an immunosuppressant that inhibits mTOR (the mammalian target of rapamycin) and extends lifespan in organisms such as worms, flies, and mice. While it is known that rapamycin’s effects on cardiac and skeletal muscle contribute to lifespan extension, it is unknown if rapamycin’s effects on the brain extend lifespan. Several proteins associated with rapamycin have decreased while other proteins have increased in the brain tissue of old mice. Moreover, these proteins have been implicated in various age-related diseases, but they have not been jointly studied with rapamycin treatment in the diseases. In this experiment, I investigated the proteins glial fibrillary acidic protein (GFAP), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1a), fibroblast growth factor 21 (FGF21), and zinc metallopeptidase STE24 (ZMPSTE24) in the brain tissue of old mice treated with rapamycin to see if rapamycin could rescue the proteins by affecting the protein expression. Brain tissue samples from male old mice were obtained; six samples were from vehicle (control, untreated) mice while six samples were from mice that received 8 mg/kg of rapamycin I.P. (high dose) injections every other day. Wet laboratory techniques, including tissue cryohomogenization and Western blots (gel electrophoresis, protein transfer, chemiluminescent detection, and film development), were used to obtain data. Rapamycin rescued PGC-1a in the brain tissue of the old mice, which suggests that rapamycin could be used in treatment for Alzheimer’s disease, Huntington’s disease, or ALS. Rapamycin may have rescued FGF21 in the brain tissue, and this suggests that rapamycin could be used in treatment for metabolic disease. Rapamycin did not rescue ZMPSTE24 or GFAP in the brain tissue.
Competition history
- ISEF 2019
Resources
Related projects
ISEF · 2017
Rapamycin as a Novel Therapeutic for Alzheimer's Disease: An Imaging Assessment of Prevention and Treatment through in vivo Brain Vasculature, Metabolism, and Cognition
ISEF · 2016
Rapamycin as a Novel Therapeutic for Alzheimer's Disease: Prevention Assessed through Neuroimaging
ISEF · 2016
Moving Towards the Cure: The Effect of Neuroinflammation and Microglial Activity on Alzheimer's Pathology and the Development of Therapeutics for Their Mitigation in the TG4510 Mouse Model (A Third Year Study)
ISEF · 2019
Silybum marianum and Rauwolfia serpentina as Novel Agents for Alzheimer's Disease Treatment and Lifespan Extension in a Caenorhabditis elegans Model
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair